Primary neuroblastoma uptake of 99mtechnetium methylene diphosphonate.
Forty patients, ages three days to 12 years, with neuroblastomas had bone scans with 99mtechnetium methylene diphosphonate (99mTc-MDP) as part of their pretreatment examination. Twenty-four (60%) had primary tumor uptake and 16 (40%) did not. No difference was seen between the two groups in the incidence of tumor calcification or necrosis. No relationship between the level of urinary vanillylmandelic acid (VMA) and the presence of primary tumor uptake of 99mTc-MDP was found. The possible causes for the localization of 99mTc-MDP are discussed.
D000310:Adrenal Gland Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism; D001842:Bone and Bones / Q000000981:diagnostic imaging / Q000378:metabolism; D002114:Calcinosis / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D004164:Diphosphonates / Q000378:metabolism*; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008479:Mediastinal Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism; D009336:Necrosis; D009447:Neuroblastoma / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology; D011877:Radionuclide Imaging; D013667:Technetium / Q000378:metabolism*; D013669:Technetium Tc 99m Medronate; D014642:Vanilmandelic Acid / Q000652:urine
D004164:Diphosphonates; D014642:Vanilmandelic Acid; D013667:Technetium; D013669:Technetium Tc 99m Medronate